Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine

Overview

Journal Front Pharmacol

Date 2019 Mar 16

PMID 30873022

Citations 49

Authors

Iwona Pranke

Anita Golec

Alexandre Hinzpeter

Aleksander Edelman

Isabelle Sermet-Gaudelus

Affiliations

Soon will be listed here.

Abstract

An improved understanding of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein structure and the consequences of gene mutations have allowed the development of novel therapies targeting specific defects underlying CF. Some strategies are mutation specific and have already reached clinical development; some strategies include a read-through of the specific premature termination codons (read-through therapies, nonsense mediated decay pathway inhibitors for Class I mutations); correction of CFTR folding and trafficking to the apical plasma membrane (correctors for Class II mutations); and an increase in the function of CFTR channel (potentiators therapy for Class III mutations and any mutant with a residual function located at the membrane). Other therapies that are in preclinical development are not mutation specific and include gene therapy to edit the genome and stem cell therapy to repair the airway tissue. These strategies that are directed at the basic CF defects are now revolutionizing the treatment for patients and should positively impact their survival rates.

Citing Articles

An FDA-approved drug structurally and phenotypically corrects the K210del mutation in genetic cardiomyopathy models.

Wang P, Ahmed M, Nguyen N, Menendez-Montes I, Hsu C, Farag A J Clin Invest. 2025; 135(4).

PMID: 39959972 PMC: 11827848. DOI: 10.1172/JCI174081.

Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights.

Shah D, Chorawala M, Pandya A, Kothari N, Prajapati B, Parekh P Curr Med Sci. 2024; 44(6):1155-1174.

PMID: 39676146 DOI: 10.1007/s11596-024-2936-5.

CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids.

Kleinfelder K, Melotti P, Hristodor A, Fevola C, Taccetti G, Terlizzi V Orphanet J Rare Dis. 2024; 19(1):343.

PMID: 39272186 PMC: 11401437. DOI: 10.1186/s13023-024-03334-3.

Current and future therapeutic approaches of CFTR and airway dysbiosis in an era of personalized medicine.

Upadhyay K, Nigam N, Gupta S, Tripathi S, Jain A, Puri B J Family Med Prim Care. 2024; 13(6):2200-2208.

PMID: 39027867 PMC: 11254065. DOI: 10.4103/jfmpc.jfmpc_1085_23.

Influence of point mutations on PR65 conformational adaptability: Insights from molecular simulations and nanoaperture optical tweezers.

Banerjee A, Mathew S, Naqvi M, Yilmaz S, Zacharopoulou M, Doruker P Sci Adv. 2024; 10(22):eadn2208.

PMID: 38820156 PMC: 11141623. DOI: 10.1126/sciadv.adn2208.

References

Walters R, Grunst T, Bergelson J, Finberg R, Welsh M, Zabner J . Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem. 1999; 274(15):10219-26. DOI: 10.1074/jbc.274.15.10219. View

Friedman K, KOLE J, Cohn J, Knowles M, Silverman L, Kole R . Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem. 1999; 274(51):36193-9. DOI: 10.1074/jbc.274.51.36193. View

Rubenstein R, Zeitlin P . Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol. 2000; 278(2):C259-67. DOI: 10.1152/ajpcell.2000.278.2.C259. View

Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A . A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med. 2000; 161(3 Pt 1):860-5. DOI: 10.1164/ajrccm.161.3.9904116. View

Joseph P, OSullivan B, Lapey A, Dorkin H, Oren J, Balfour R . Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther. 2001; 12(11):1369-82. DOI: 10.1089/104303401750298535. View

Harvey B, Maroni J, ODonoghue K, Chu K, Muscat J, Pippo A . Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther. 2002; 13(1):15-63. DOI: 10.1089/10430340152712638. View

Gelman M, Kannegaard E, Kopito R . A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator. J Biol Chem. 2002; 277(14):11709-14. DOI: 10.1074/jbc.M111958200. View

Aleksandrov A, Aleksandrov L, Riordan J . Nucleoside triphosphate pentose ring impact on CFTR gating and hydrolysis. FEBS Lett. 2002; 518(1-3):183-8. DOI: 10.1016/s0014-5793(02)02698-4. View

Zeitlin P, Diener-West M, Rubenstein R, Boyle M, Lee C, Brass-Ernst L . Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther. 2002; 6(1):119-26. DOI: 10.1006/mthe.2002.0639. View

10.

Gregory L, Harbottle R, Lawrence L, Knapton H, Themis M, Coutelle C . Enhancement of adenovirus-mediated gene transfer to the airways by DEAE dextran and sodium caprate in vivo. Mol Ther. 2003; 7(1):19-26. DOI: 10.1016/s1525-0016(02)00021-7. View

11.

Yang H, Shelat A, Guy R, Gopinath V, Ma T, Du K . Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem. 2003; 278(37):35079-85. DOI: 10.1074/jbc.M303098200. View

12.

Rosenfeld M, Yoshimura K, Trapnell B, Yoneyama K, Rosenthal E, Dalemans W . In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 1992; 68(1):143-55. DOI: 10.1016/0092-8674(92)90213-v. View

13.

Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J . Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003; 349(15):1433-41. DOI: 10.1056/NEJMoa022170. View

14.

Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K . Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol. 2004; 164(6):923-33. PMC: 2172283. DOI: 10.1083/jcb.200312018. View

15.

Maquat L . Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol. 2004; 5(2):89-99. DOI: 10.1038/nrm1310. View

16.

Varga K, Jurkuvenaite A, Wakefield J, Hong J, Guimbellot J, Venglarik C . Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines. J Biol Chem. 2004; 279(21):22578-84. DOI: 10.1074/jbc.M401522200. View

17.

Egan M, Pearson M, Weiner S, Rajendran V, Rubin D, Glockner-Pagel J . Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004; 304(5670):600-2. DOI: 10.1126/science.1093941. View

18.

Zamecnik P, Raychowdhury M, Tabatadze D, Cantiello H . Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. Proc Natl Acad Sci U S A. 2004; 101(21):8150-5. PMC: 419572. DOI: 10.1073/pnas.0401933101. View

19.

Berger A, Randak C, Ostedgaard L, Karp P, Vermeer D, Welsh M . Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl- channel activity. J Biol Chem. 2004; 280(7):5221-6. DOI: 10.1074/jbc.M412972200. View

20.

Du K, Sharma M, Lukacs G . The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol. 2004; 12(1):17-25. DOI: 10.1038/nsmb882. View